RxDoctor Payments Data

Nuttapoom Yoadjarust, PA

Physician Assistant · New York, NYNPI 1447742028

Payments from drug & device makers

$17,881in general payments, 2019–2025

Across 732 payments — averaging $24.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$3K
  • AstraZeneca$3K
  • Sanofi$2K
  • Regeneron Healthcare Solutions, Inc.$1K
  • Kaleo, Inc.$1K
  • Novartis$851
  • plus $5K from 23 others

What the payments were for

  • Speaking & faculty fees$2501%
  • Food & beverage$17,53298%
  • Education$991%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,881 in reported general payments places this provider in the 95th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$9,782
Medicare patients
49
Services billed
422

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent SyringeDupilumab13$49,330
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$30,447
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$7,592
Epinephrine13$3,010
Albuterol Sulfate HfaAlbuterol Sulfate41$1,402
Azelastine Hcl51$1,324
Fluticasone Propionate46$465
Levocetirizine Dihydrochloride32$405
Montelukast Sodium21$157

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$3,424$30,44742 claims
AstraZenecaBreztri Aerosphere$3,421$7,59212 claims
Hikma Pharmaceuticals USAEpinephrine$123$3,01013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →